Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 06, 2023

SELL
$1.15 - $1.67 $175,345 - $254,631
-152,474 Reduced 86.05%
24,726 $31,000
Q3 2022

Nov 01, 2022

BUY
$0.82 - $1.73 $145,304 - $306,556
177,200 New
177,200 $153,000

Others Institutions Holding MREO

About Mereo Biopharma Group plc


  • Ticker MREO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,986,000
  • Market Cap $419M
  • Description
  • Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...
More about MREO
Track This Portfolio

Track Privium Fund Management (Uk) LTD Portfolio

Follow Privium Fund Management (Uk) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Privium Fund Management (Uk) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Privium Fund Management (Uk) LTD with notifications on news.